Glenmark Launches BRUKINSA in India for B-Cell Cancers

  Published 1 year ago

Glenmark launches BRUKINSA, India's first BTK inhibitor for five B-cell cancers approved by DCGI with global trials and lower cardiac risks.

  • Treats CLL/SLL, WM, MCL, MZL, FL with proven efficacy and safety from ALPINE, ASPEN, SEQUOIA trials.
  • Addresses India's blood cancer burden with high response rates and flexible dosing for personalized care.
  • Shows 1.9% vs. 7.7% serious cardiac events vs. ibrutinib in relapsed/refractory CLL studies.

You might like these

GCPL GST Cut Spurs Demand, Hits Profit

Eicher Motors Sales Surge in June 2025

Hindalco Q4 Beats, Faces Headwinds

RBI: 98.29% of Rs 2000 Notes Returned

RailTel Bags Rs 259 Crore Orders for School Supplies in HP & Bihar

Saudi Pharma JV Boosts Local Production

ITD Cementation India: Engineering Excellence in Infrastructure

News that matters the most ⚡